Should our patient’s tumor prove an index case of a specific, high-grade, thyrocyte-differentiated, NUTM1 fusion thyroid carcinoma, discovery of more examples will establish the range of pathology features, tumor behavior, and response to therapies such as BETi agents and immune checkpoint inhibitors. The gene discussed is NUTM1; the disease is neoplasm.